Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Nick van Dijk, Alberto Gil-Jimenez, Karīna Siliņa, et al.
Nature Medicine (2020) Vol. 26, Iss. 12, pp. 1839-1844
Closed Access | Times Cited: 323

Showing 1-25 of 323 citing articles:

Tertiary lymphoid structures in cancer
Ton N. Schumacher, Daniela S. Thommen
Science (2022) Vol. 375, Iss. 6576
Closed Access | Times Cited: 660
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 4, pp. 525-537
Open Access | Times Cited: 316
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Céline M. Laumont, Allyson C. Banville, Mara Gilardi, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 7, pp. 414-430
Open Access | Times Cited: 316
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 286
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
Joris L. Vos, Joris B.W. Elbers, Oscar Krijgsman, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 209
The roles of tertiary lymphoid structures in chronic diseases
Yuki Sato, Karīna Siliņa, Maries van den Broek, et al.
Nature Reviews Nephrology (2023) Vol. 19, Iss. 8, pp. 525-537
Open Access | Times Cited: 131
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados, Mark Kockx, Zoe J. Assaf, et al.
European Urology (2022) Vol. 82, Iss. 2, pp. 212-222
Open Access | Times Cited: 124
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
Wolf H. Fridman, Maxime Meylan, Guilhem Pupier, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2254-2269
Open Access | Times Cited: 122
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy
Clarice S. Groeneveld, Jacqueline Fontugne, Luc Cabel, et al.
European Journal of Cancer (2021) Vol. 148, pp. 181-189
Closed Access | Times Cited: 114
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies
Nicolas Jacquelot, Julie Tellier, Stephen L. Nutt, et al.
OncoImmunology (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 109
B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity
Céline M. Laumont, Brad H. Nelson
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 466-489
Open Access | Times Cited: 96
Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Shitao Jiang, Y. Liu, Han Zheng, et al.
International Journal of Surgery (2023)
Open Access | Times Cited: 88
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
Judith M. Versluis, Alexander M. Menzies, Karolina Sikorska, et al.
Annals of Oncology (2023) Vol. 34, Iss. 4, pp. 420-430
Open Access | Times Cited: 74
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
Giuseppe Basile, Marco Bandini, Ewan A. Gibb, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 23, pp. 5107-5114
Open Access | Times Cited: 71
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Weijie Ma, Ruobing Xue, Zheng Zhu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 65
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Zhichao Liu, Yaru Zhang, Ning Ma, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1852-1870.e9
Open Access | Times Cited: 59
Tertiary lymphoid structures in anticancer immunity
Jean‐Luc Teillaud, Ana Houel, Marylou Panouillot, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 9, pp. 629-646
Closed Access | Times Cited: 35
Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application
Yuyuan Zhang, Mengjun Xu, Yuqing Ren, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 26
Tertiary lymphoid structures in cancer: maturation and induction
Yulu Chen, Yuhao Wu, Guorong Yan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 20
Exploiting temporal aspects of cancer immunotherapy
Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 7, pp. 480-497
Closed Access | Times Cited: 17
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Miguel López de Rodas, María Villalba, Miguel F. Sanmamed, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 7
Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer
Wei‐Yi Chen, Lingli Zhang, Man Gao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Florent Peyraud, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.
Med (2025) Vol. 6, Iss. 1, pp. 100546-100546
Closed Access | Times Cited: 2
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition
Noah F. Greenwald, Iris Nederlof, C. H. Sowers, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 2
B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
Martin Lauss, Marco Donia, Inge Marie Svane, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 9, pp. 1751-1758
Open Access | Times Cited: 82
Page 1 - Next Page

Scroll to top